Therapeutic strategies targeting Cer metabolism are explored, including neutral sphingomyelinase inhibitors for hypertension, dietary DHA/EPA supplementation for dyslipidemia and the pharmacological approach of the anti-diabetic, metformin. Here, CBLN1 is linked to metabolic syndrome.